Generation Bio Co. (NASDAQ:GBIO) Short Interest Up 10.5% in June

Generation Bio Co. (NASDAQ:GBIO) saw a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 1,680,000 shares, an increase of 10.5% from the June 15th total of 1,520,000 shares. Currently, 3.5% of the shares of the company are short sold. Based on an average daily volume of 172,900 shares, the days-to-cover ratio is presently 9.7 days.

Analyst Ratings Changes

Several equities analysts have issued reports on GBIO shares. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Generation Bio in a report on Tuesday, May 14th. Wedbush reissued an “outperform” rating and set a $5.00 price target on shares of Generation Bio in a report on Tuesday, May 14th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Generation Bio Stock Performance

NASDAQ:GBIO traded up $0.26 during mid-day trading on Tuesday, reaching $3.19. The stock had a trading volume of 133,453 shares, compared to its average volume of 226,340. The firm has a market capitalization of $212.23 million, a price-to-earnings ratio of -1.18 and a beta of 2.84. Generation Bio has a twelve month low of $0.86 and a twelve month high of $5.69. The business has a 50 day simple moving average of $2.98 and a 200 day simple moving average of $2.77.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings data on Monday, May 13th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.76). The firm had revenue of $4.06 million during the quarter, compared to analyst estimates of $3.02 million. Generation Bio had a negative net margin of 1,696.87% and a negative return on equity of 82.33%. As a group, sell-side analysts expect that Generation Bio will post -1.68 earnings per share for the current year.

Institutional Investors Weigh In On Generation Bio

Hedge funds have recently added to or reduced their stakes in the company. PFG Advisors acquired a new stake in shares of Generation Bio during the 1st quarter valued at approximately $41,000. Panagora Asset Management Inc. acquired a new stake in shares of Generation Bio during the 4th quarter valued at approximately $49,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Generation Bio during the 4th quarter valued at approximately $50,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Generation Bio during the 1st quarter valued at approximately $74,000. Finally, SG Americas Securities LLC lifted its position in shares of Generation Bio by 260.9% during the 4th quarter. SG Americas Securities LLC now owns 48,470 shares of the company’s stock valued at $80,000 after acquiring an additional 35,040 shares during the period. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.